Sector Gamma AS grew its stake in Johnson & Johnson (NYSE:JNJ) by 88.6% during the 3rd quarter, Holdings Channel reports. The fund owned 57,116 shares of the company’s stock after acquiring an additional 26,837 shares during the period. Johnson & Johnson comprises about 1.9% of Sector Gamma AS’s portfolio, making the stock its 21st biggest position. Sector Gamma AS’s holdings in Johnson & Johnson were worth $8,503,000 as of its most recent SEC filing.
Several other large investors also recently modified their holdings of the company. Morgan Stanley lifted its position in Johnson & Johnson by 0.3% during the first quarter. Morgan Stanley now owns 20,801,433 shares of the company’s stock worth $2,727,694,000 after buying an additional 54,563 shares during the period. Price Wealth LLC lifted its position in Johnson & Johnson by 8.6% during the second quarter. Price Wealth LLC now owns 1,270 shares of the company’s stock worth $179,000 after buying an additional 101 shares during the period. Financial Advisory Service Inc. lifted its position in Johnson & Johnson by 2.5% during the second quarter. Financial Advisory Service Inc. now owns 17,970 shares of the company’s stock worth $2,527,000 after buying an additional 431 shares during the period. Abundance Wealth Counselors lifted its position in Johnson & Johnson by 183.3% during the second quarter. Abundance Wealth Counselors now owns 7,109 shares of the company’s stock worth $1,000,000 after buying an additional 4,600 shares during the period. Finally, Adams Asset Advisors LLC lifted its position in Johnson & Johnson by 178.6% during the second quarter. Adams Asset Advisors LLC now owns 15,980 shares of the company’s stock worth $2,247,000 after buying an additional 10,245 shares during the period. Institutional investors and hedge funds own 67.44% of the company’s stock.
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 16,115 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the completion of the sale, the executive vice president now owns 66,658 shares in the company, valued at approximately $10,233,336.16. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.27% of the stock is owned by company insiders.
JNJ stock opened at $146.36 on Friday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.24 and a current ratio of 1.48. Johnson & Johnson has a 1 year low of $109.16 and a 1 year high of $157.00. The firm has a market cap of $385.30 billion, a P/E ratio of 23.01, a price-to-earnings-growth ratio of 3.04 and a beta of 0.69. The stock has a 50-day simple moving average of $145.51 and a 200-day simple moving average of $146.57.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Sunday, October 18th. The company reported $2.20 earnings per share for the quarter, beating analysts’ consensus estimates of $1.98 by $0.22. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. The firm had revenue of $21.08 billion during the quarter, compared to analyst estimates of $20.15 billion. During the same quarter last year, the firm earned $2.12 EPS. Johnson & Johnson’s quarterly revenue was up 1.7% on a year-over-year basis. On average, equities research analysts predict that Johnson & Johnson will post 7.99 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be paid a dividend of $1.01 per share. The ex-dividend date is Monday, November 23rd. This represents a $4.04 dividend on an annualized basis and a yield of 2.76%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.54%.
Several equities analysts recently weighed in on JNJ shares. Stifel Nicolaus downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Credit Suisse Group raised their price objective on Johnson & Johnson from $163.00 to $168.00 and gave the stock an “outperform” rating in a report on Wednesday, October 14th. Raymond James restated a “buy” rating on shares of Johnson & Johnson in a report on Friday. ValuEngine upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Monday, August 3rd. Finally, Cantor Fitzgerald raised their price objective on Johnson & Johnson from $168.00 to $180.00 and gave the stock an “overweight” rating in a report on Wednesday, October 14th. One research analyst has rated the stock with a sell rating, four have given a hold rating and ten have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $164.93.
About Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
Recommended Story: Diversification in Investing
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.